Needham analyst David Saxon reiterated a Buy rating on CryoPort today and set a price target of $12.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
David Saxon has given his Buy rating due to a combination of factors including CryoPort’s impressive third-quarter revenue performance, which surpassed market expectations. The company’s success was largely driven by its Life Sciences Services segment, and management has subsequently increased its revenue guidance for 2025.
Additionally, there is potential for further revenue growth in 2026, as suggested by management’s commentary. CryoPort is also making strides towards achieving adjusted EBITDA profitability, with the possibility of reaching this milestone by the fourth quarter of 2025. These positive developments have led to an increased price target of $12, reinforcing the Buy rating.